Loading page…

Report overview

The report describes a strong 2021 commercial year, with Group turnover of £34.1 billion and 5% CER growth. It reports three major product approvals and a pipeline of 21 vaccines and 43 medicines, while GSK advanced its plans to separate Consumer Healthcare into Haleon in mid-2022. The report also highlights the company's net-zero climate and nature-positive goals for 2030 and its leading ESG rankings.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2021
Period: 1 January 2021 – 31 December 2021
Publication date: 28 February 2022
Language
Pages
File size
Restatement: Disclosed

Standards & Assurance

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

SBTi status
CDP score

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

ESG & Materiality

ESG data

Indicators available in this report:

Scope 1 emissions
Scope 3 emissions
Energy consumption
Employees
Women on the board
Workplace fatalities
Net zero target

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown for your project.

Explore our services